Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03057730 · ClinicalTrials.gov registry record · Phase 4
A Clinical Trial Testing Root Coverage With Acellular Dermal Matrix in Thin and Thick Gingival Biotypes
A Phase 4 study of Gingival Recession, sponsored by Tufts University.
- Active
- Registry status
- Phase 4
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT03057730: Active Phase 4 study of Gingival Recession, sponsored by Tufts University.
NCT03057730 is a Phase 4 study of Gingival Recession that is active but no longer recruiting, run by Tufts University. The registered enrollment target is 34 participants, above the 30-participant average among 10 other Gingival Recession trials with a reported enrollment target (13% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03057730, a Phase 4 study of Gingival Recession, is active but no longer recruiting, sponsored by Tufts University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
Gingival recession is a common defect among the American population. It is also a major cause for root decay, hypersensitivity, contributes to tooth mobility and low self-esteem. Acellular dermal matrix, a human-derived grafting material has been put on the market for the treatment of gingival recession. Treating gingival recession with this material has been a validated treatment option for years. However, treatment outcomes in two patient populations, namely those with thin biotypes and those with thick biotypes, has not been investigated. This study will observe the primary treatment outcomes in the two patient groups at 5 time points - 3 months, 6 months and 12 months post-surgery to observe short term outcomes; additional 24 months and 48 months post-surgery to observe long term outcomes.
Conditions Studied
Interventions
- BIOLOGICAL Acellular Dermal Matrix
Study Locations (1)
Massachusetts
- Tufts University School of Dental Medicine - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2015-08 |
| Est. Completion | 2025-09 |
| Phase | Phase 4 |
What the registry record for NCT03057730 still lists
NCT03057730 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, above the 30-participant average among 10 other Gingival Recession trials with a reported enrollment target (13% higher).
The record links to 1 condition, with Gingival Recession appearing as the primary indexed condition, and to 1 intervention - of which Acellular Dermal Matrix is the first listed.
NCT03057730 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03057730 about?
NCT03057730 is a clinical study titled "A Clinical Trial Testing Root Coverage With Acellular Dermal Matrix in Thin and Thick Gingival Biotypes". Gingival recession is a common defect among the American population. It is also a major cause for root decay, hypersensitivity, contributes to tooth mobility and low self-esteem. Acellular dermal matrix, a human-derived grafting material has been put on the market for the treatment of gingival reces...
What is the current status of trial NCT03057730?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 34 participants. The study started on 2015-08. Estimated completion is 2025-09.
What conditions does trial NCT03057730 study?
This clinical trial studies the following conditions: Gingival Recession.
What interventions are being tested in trial NCT03057730?
The interventions under investigation include: Acellular Dermal Matrix (BIOLOGICAL).
Who is sponsoring clinical trial NCT03057730?
This trial is sponsored by Tufts University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03057730 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gingival Recession
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03057730's enrollment target sits among peer trials
34 5th of 10 higher than 6 of 10 other Gingival Recession trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gingival Recession trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gain of Keratinized Mucosa Around Teeth and Dental Implants Using a Combination of Strip Gingival Graft and Acellular Dermal Matrix
RECRUITING · NA
-
Patient-reported Outcomes of Donor Site Healing Using Different Palatal Protection Techniques
RECRUITING · NA
-
Changes of Soft Tissue Grafting: A Randomized Study
RECRUITING · NA
-
A Comparison of Side Access Mucosal Releasing Incision (SAMRI) and Sulcular Tunnel Access to Treat Gingival Recession.
ACTIVE NOT RECRUITING · NA
-
Thick vs. Thin Acellular Dermal Matrix (ADM)
COMPLETED · NA
-
Evaluation of Geistlich Fibro-Gide® + CAF in Comparison to CTG + CAF for the Treatment of Recession Defects at 6 Months
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia